By Publisher Team
Press Release: Mahamaya Lifesciences Announces ₹70.44 Crore IPO; Opens November 11, 2025
Mahamaya Lifesciences Limited (“the Company”), a leading manufacturer and exporter of crop protection products and bioproducts, has announced the launch of its Initial Public Offering (IPO) to raise ₹70.44 crores through a Book Building issue.
IPO Price & Market Lot Structure
- Fresh Issue: 53,29,200 shares (aggregating up to ₹60.75 Cr)
- Offer-for-Sale: 5,40,000 shares of ₹10 (aggregating up to ₹6.16 Cr)
- Price Band: ₹108 – ₹114 per share (Face value ₹10 each)
- Lot Size: 1,200 shares
- Minimum Retail Investment: ₹2,73,600 for 2 lots (2,400 shares)
- Minimum S-HNI Investment: ₹4,10,400 for 3 lots (3,600 shares)
- Anchor Investor Portion: Activated on November 10, 2025, raising ₹19.97 crores.
Issue Allocation Breakdown
Category | Shares Offered | % of Issue |
|---|---|---|
QIB | 29,28,000 | 47.39% |
NII / HNI | 8,82,000 | 14.27% |
Retail Investors | 20,59,200 | 33.33% |
Market Maker | 3,09,600 | 5.01% |
Utilization of Net Proceeds
- Equipment for Existing Formulation Plant: ₹3.75 Cr
- New Technical Manufacturing Plant Capex: ₹29.42 Cr
- Warehouse Construction & Machinery: ₹2.53 Cr
- Working Capital: ₹18.00 Cr
- General Corporate Purposes: Balance
About the Company & Global Reach
Incorporated in 2002, Mahamaya Lifesciences is engaged in manufacturing, registration, and export of pesticide formulations and branded bioproducts. The Company supplies bulk formulations to leading Indian agrochemical brands and multinational corporations, holding global product registrations in countries including Dominican Republic, Egypt, Ethiopia, Jordan, UAE & Turkey.
Key Products include Acetamiprid, Buprofezin, Emamectin Benzoate, Imidacloprid & Paraquat Dichloride in multiple technical & formulation variants.
Financial Performance (Restated Consolidated)
- FY 2024–25 Revenue: ₹267.17 Cr (64% YoY growth) | PAT: ₹12.94 Cr (148% YoY growth)
- EBITDA Margin: 9.22% | RoE: 34.94% | RoCE: 23.15%
- FY 2023–24 Revenue: ₹162.83 Cr | PAT: ₹5.22 Cr
“This IPO strengthens our vision to enhance India’s food security through innovation in crop protection, while expanding our capacity to serve global agriculture.”
— Managing Director, Mahamaya Lifesciences Ltd.
Related News
Mahamaya Lifesciences Wins “Company of the Year – Medium Scale” Award at ICSCE 2026, Dubai
Mahamaya Lifesciences Limited has been honoured with the prestigious “Company of the Year – Medium Scale” Award at the PMFAI SML Awards 2026 during ICSCE in Dubai.
Read More
Mahamaya Lifesciences Limited – IPO Launch Announcement & Key Highlights
Mahamaya Lifesciences Limited launches its Initial Public Offering (IPO) of up to ₹70.44 Cr. Issue opens November 11, 2025 and closes November 13, 2025.
Read More
Mahamaya Lifesciences Collaborates with ICAR-CISH to Promote Sustainable Agriculture
Mahamaya Lifesciences Limited has collaborated with ICAR-CISH, Lucknow, under its CSR initiative to demonstrate and promote scientifically validated, eco-friendly agricultural technologies that support sustainable crop production, improved produce quality and better outcomes for farmers.
Read More